Drug intelligence / Profile preview

IDC2403

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IDC2403 is a monoclonal antibody biosimilar candidate developed by Prestige Biopharma (PBK) that targets the CD20 antigen. It is designed as a biosimilar to ocrelizumab (Ocrevus) for the treatment of multiple sclerosis. The drug's mechanism of action involves binding to CD20 on the surface of B-lymphocytes, which triggers their depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). By reducing the population of circulating B-cells, IDC2403 aims to decrease the inflammatory activity and neuroaxonal damage associated with multiple sclerosis. It is currently in the preclinical stage of development.

Other names: ocrelizumab biosimilar

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on IDC2403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC2403.

Explore the full profile